A reduction of the FDG maximum standardized uptake value is superior to visual analysis for the evaluation of treatment response in patients with Hodgkin’s lymphoma, according to a study published online Feb. 24 in the Journal of Nuclear Medicine . {read more here}

Molecular imaging is beginning to give cardiologists insight into biological processes behind heart failure, knowledge that may allow them to monitor disease progression and tailor therapies. But market realities still pose barriers. {read more here}

German researchers have confirmed the efficacy of PET/CT with the radiopharmaceutical gallium-68 (Ga-68) DOTATATE for detecting the recurrence of neuroendocrine tumors (NETs), in a study published in the February issue of Radiology. {read more here}

“Alzheimer’s disease is probably the most underfunded disease in the U.S.,” charges Dean M. Hartley, PhD, director of science initiatives, medical and scientific relations, for the Alzheimer’s Association. And money matters. A cursory review of the history of major diseases like cancer and heart disease shows that cures are proportional to research dollars, continues Hartley. It’s not only the disproportionate funding that has Alzheimer’s stakeholders up in arms. The July 2013 draft decision by CMS to limit reimbursement for florbetapir PET to coverage with evidence development represents a potentially devastating blow to the dissemination of amyloid PET imaging. {read more here}